Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity / Margaret H. SIBLEY in Journal of Child Psychology and Psychiatry, 58-6 (June 2017)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.655-662 Titre : Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity Type de document : Texte imprimé et/ou numérique Auteurs : Margaret H. SIBLEY, Auteur ; James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Lily T. HECHTMAN, Auteur ; Elizabeth B. OWENS, Auteur ; Annamarie STEHLI, Auteur ; Howard B. ABIKOFF, Auteur ; Stephen P. HINSHAW, Auteur ; Brooke S. G. MOLINA, Auteur ; John T. MITCHELL, Auteur ; Peter S. JENSEN, Auteur ; Andrea L. HOWARD, Auteur ; Kimberley D. LAKES, Auteur ; William E. PELHAM, Auteur ; THE M. T. A. COOPERATIVE GROUP,, Auteur Article en page(s) : p.655-662 Langues : Anglais (eng) Mots-clés : Adult ADHD  DSM-5  diagnosis Index. décimale : PER Périodiques Résumé : Objective Longitudinal studies of children diagnosed with ADHD report widely ranging ADHD persistence rates in adulthood (5–75%). This study documents how information source (parent vs. self-report), method (rating scale vs. interview), and symptom threshold (DSM vs. norm-based) influence reported ADHD persistence rates in adulthood. Method Five hundred seventy-nine children were diagnosed with DSM-IV ADHD-Combined Type at baseline (ages 7.0–9.9 years) 289 classmates served as a local normative comparison group (LNCG), 476 and 241 of whom respectively were evaluated in adulthood (Mean Age = 24.7). Parent and self-reports of symptoms and impairment on rating scales and structured interviews were used to investigate ADHD persistence in adulthood. Results Persistence rates were higher when using parent rather than self-reports, structured interviews rather than rating scales (for self-report but not parent report), and a norm-based (NB) threshold of 4 symptoms rather than DSM criteria. Receiver-Operating Characteristics (ROC) analyses revealed that sensitivity and specificity were optimized by combining parent and self-reports on a rating scale and applying a NB threshold. Conclusion The interview format optimizes young adult self-reporting when parent reports are not available. However, the combination of parent and self-reports from rating scales, using an ‘or’ rule and a NB threshold optimized the balance between sensitivity and specificity. With this definition, 60% of the ADHD group demonstrated symptom persistence and 41% met both symptom and impairment criteria in adulthood. En ligne : http://dx.doi.org/10.1111/jcpp.12620 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308 [article] Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity [Texte imprimé et/ou numérique] / Margaret H. SIBLEY, Auteur ; James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Lily T. HECHTMAN, Auteur ; Elizabeth B. OWENS, Auteur ; Annamarie STEHLI, Auteur ; Howard B. ABIKOFF, Auteur ; Stephen P. HINSHAW, Auteur ; Brooke S. G. MOLINA, Auteur ; John T. MITCHELL, Auteur ; Peter S. JENSEN, Auteur ; Andrea L. HOWARD, Auteur ; Kimberley D. LAKES, Auteur ; William E. PELHAM, Auteur ; THE M. T. A. COOPERATIVE GROUP,, Auteur . - p.655-662. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.655-662 Mots-clés : Adult ADHD  DSM-5  diagnosis Index. décimale : PER Périodiques Résumé : Objective Longitudinal studies of children diagnosed with ADHD report widely ranging ADHD persistence rates in adulthood (5–75%). This study documents how information source (parent vs. self-report), method (rating scale vs. interview), and symptom threshold (DSM vs. norm-based) influence reported ADHD persistence rates in adulthood. Method Five hundred seventy-nine children were diagnosed with DSM-IV ADHD-Combined Type at baseline (ages 7.0–9.9 years) 289 classmates served as a local normative comparison group (LNCG), 476 and 241 of whom respectively were evaluated in adulthood (Mean Age = 24.7). Parent and self-reports of symptoms and impairment on rating scales and structured interviews were used to investigate ADHD persistence in adulthood. Results Persistence rates were higher when using parent rather than self-reports, structured interviews rather than rating scales (for self-report but not parent report), and a norm-based (NB) threshold of 4 symptoms rather than DSM criteria. Receiver-Operating Characteristics (ROC) analyses revealed that sensitivity and specificity were optimized by combining parent and self-reports on a rating scale and applying a NB threshold. Conclusion The interview format optimizes young adult self-reporting when parent reports are not available. However, the combination of parent and self-reports from rating scales, using an ‘or’ rule and a NB threshold optimized the balance between sensitivity and specificity. With this definition, 60% of the ADHD group demonstrated symptom persistence and 41% met both symptom and impairment criteria in adulthood. En ligne : http://dx.doi.org/10.1111/jcpp.12620 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308

Research Review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit/hyperactivity disorder - a systematic review of the literature / Margaret H. SIBLEY in Journal of Child Psychology and Psychiatry, 66-1 (January 2025)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 66-1 (January 2025) . - p.132-149 Titre : Research Review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit/hyperactivity disorder - a systematic review of the literature Type de document : Texte imprimé et/ou numérique Auteurs : Margaret H. SIBLEY, Auteur ; Sabrina FLORES, Auteur ; Madeline MURPHY, Auteur ; Hana BASU, Auteur ; Mark A. STEIN, Auteur ; Steven W. EVANS, Auteur ; Xin ZHAO, Auteur ; Maychelle MANZANO, Auteur ; Shauntal VAN DREEL, Auteur Article en page(s) : p.132-149 Langues : Anglais (eng) Mots-clés : ADHD  adolescence  treatment trials Index. décimale : PER Périodiques Résumé : Background Attention Deficit/Hyperactivity Disorder (ADHD) demonstrates unique developmental manifestations in adolescence with implications for optimized, age-appropriate treatment. This 10-year update is the third in a series of systematic reviews examining the efficacy and safety of adolescent ADHD treatments. We broadly examined efficacy on ADHD symptoms, impairments, and other reported outcomes. Acute and long-term efficacy, and treatment moderators, were considered. Method We performed PubMed, EMBASE, and PsycINFO searches for articles published or in press from 2013 to 2024, integrated with hand search and randomized controlled trials (RCTs) identified in this series' earlier reviews. RCTs examining the safety or efficacy of interventions delivered to adolescents (ages 10.0?19.9) with a diagnosis of ADHD were included. Study characteristics were extracted and reviewed, quality of evidence was assessed using GRADE, and effect sizes were calculated for individual studies and illustrated using forest plots. Results Sixty-three RCTs were identified. Quality of evidence ranged from high (medication; k?=?29) to very low (nutrient supplementation, neurofeedback, occupational therapy; k?=?1 each). Medications demonstrated consistent strong impact on ADHD symptoms and inconsistent impact on impairment. Diverse cognitive/behavioral treatments (C/BTs) demonstrated inconsistent impact on ADHD symptoms but strong and consistent impact on impairment and executive function skills, plus moderate benefits on internalizing symptoms. No interventions demonstrated significant safety concerns. Long-term maintenance (up to 3?years post-treatment) was demonstrated for C/BTs, though moderate quality of evidence was noted because participants cannot be fully blinded to receipt of treatment. Conclusions The effects of C/BTs and medication appear complementary, not duplicative. Combining medication and C/BT is advised at treatment outset to maximize engagement, maintenance, and response breadth (i.e. improving both ADHD symptoms/cognitive performance and coping skills/functional impairments). Engagement strategies (e.g. motivational interviewing) may facilitate uptake. Novel treatments do not yet demonstrate effects on ADHD symptoms or impairments in adolescents but remain a promising area for research. En ligne : https://dx.doi.org/10.1111/jcpp.14056 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=545 [article] Research Review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit/hyperactivity disorder - a systematic review of the literature [Texte imprimé et/ou numérique] / Margaret H. SIBLEY, Auteur ; Sabrina FLORES, Auteur ; Madeline MURPHY, Auteur ; Hana BASU, Auteur ; Mark A. STEIN, Auteur ; Steven W. EVANS, Auteur ; Xin ZHAO, Auteur ; Maychelle MANZANO, Auteur ; Shauntal VAN DREEL, Auteur . - p.132-149. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 66-1 (January 2025) . - p.132-149 Mots-clés : ADHD  adolescence  treatment trials Index. décimale : PER Périodiques Résumé : Background Attention Deficit/Hyperactivity Disorder (ADHD) demonstrates unique developmental manifestations in adolescence with implications for optimized, age-appropriate treatment. This 10-year update is the third in a series of systematic reviews examining the efficacy and safety of adolescent ADHD treatments. We broadly examined efficacy on ADHD symptoms, impairments, and other reported outcomes. Acute and long-term efficacy, and treatment moderators, were considered. Method We performed PubMed, EMBASE, and PsycINFO searches for articles published or in press from 2013 to 2024, integrated with hand search and randomized controlled trials (RCTs) identified in this series' earlier reviews. RCTs examining the safety or efficacy of interventions delivered to adolescents (ages 10.0?19.9) with a diagnosis of ADHD were included. Study characteristics were extracted and reviewed, quality of evidence was assessed using GRADE, and effect sizes were calculated for individual studies and illustrated using forest plots. Results Sixty-three RCTs were identified. Quality of evidence ranged from high (medication; k?=?29) to very low (nutrient supplementation, neurofeedback, occupational therapy; k?=?1 each). Medications demonstrated consistent strong impact on ADHD symptoms and inconsistent impact on impairment. Diverse cognitive/behavioral treatments (C/BTs) demonstrated inconsistent impact on ADHD symptoms but strong and consistent impact on impairment and executive function skills, plus moderate benefits on internalizing symptoms. No interventions demonstrated significant safety concerns. Long-term maintenance (up to 3?years post-treatment) was demonstrated for C/BTs, though moderate quality of evidence was noted because participants cannot be fully blinded to receipt of treatment. Conclusions The effects of C/BTs and medication appear complementary, not duplicative. Combining medication and C/BT is advised at treatment outset to maximize engagement, maintenance, and response breadth (i.e. improving both ADHD symptoms/cognitive performance and coping skills/functional impairments). Engagement strategies (e.g. motivational interviewing) may facilitate uptake. Novel treatments do not yet demonstrate effects on ADHD symptoms or impairments in adolescents but remain a promising area for research. En ligne : https://dx.doi.org/10.1111/jcpp.14056 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=545

Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression / James M. SWANSON in Journal of Child Psychology and Psychiatry, 58-6 (June 2017)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.663-678 Titre : Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression Type de document : Texte imprimé et/ou numérique Auteurs : James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Brooke S. G. MOLINA, Auteur ; Margaret H. SIBLEY, Auteur ; Lily T. HECHTMAN, Auteur ; Stephen P. HINSHAW, Auteur ; Howard B. ABIKOFF, Auteur ; Annamarie STEHLI, Auteur ; Elizabeth B. OWENS, Auteur ; John T. MITCHELL, Auteur ; Quyen NICHOLS, Auteur ; Andrea HOWARD, Auteur ; Laurence L. GREENHILL, Auteur ; Betsy HOZA, Auteur ; Jeffrey H. NEWCORN, Auteur ; Peter S. JENSEN, Auteur ; Benedetto VITIELLO, Auteur ; Timothy WIGAL, Auteur ; Jeffery N. EPSTEIN, Auteur ; Leanne TAMM, Auteur ; Kimberly D. LAKES, Auteur ; James WAXMONSKY, Auteur ; Marc LERNER, Auteur ; Joy ETCOVITCH, Auteur ; Desiree W. MURRAY, Auteur ; Maximilian MUENKE, Auteur ; Maria T. ACOSTA, Auteur ; Mauricio ARCOS-BURGOS, Auteur ; William E. PELHAM, Auteur ; Helena C. KRAEMER, Auteur ; THE M. T. A. COOPERATIVE GROUP,, Auteur Article en page(s) : p.663-678 Langues : Anglais (eng) Mots-clés : Attention-deficit/hyperactivity disorder  follow-up studies  growth  longitudinal studies  treatment trials  medication effects Index. décimale : PER Périodiques Résumé : Background The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7–10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2–16 years after baseline. Methods Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. Results For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38). Conclusions In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity. En ligne : http://dx.doi.org/10.1111/jcpp.12684 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308 [article] Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression [Texte imprimé et/ou numérique] / James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Brooke S. G. MOLINA, Auteur ; Margaret H. SIBLEY, Auteur ; Lily T. HECHTMAN, Auteur ; Stephen P. HINSHAW, Auteur ; Howard B. ABIKOFF, Auteur ; Annamarie STEHLI, Auteur ; Elizabeth B. OWENS, Auteur ; John T. MITCHELL, Auteur ; Quyen NICHOLS, Auteur ; Andrea HOWARD, Auteur ; Laurence L. GREENHILL, Auteur ; Betsy HOZA, Auteur ; Jeffrey H. NEWCORN, Auteur ; Peter S. JENSEN, Auteur ; Benedetto VITIELLO, Auteur ; Timothy WIGAL, Auteur ; Jeffery N. EPSTEIN, Auteur ; Leanne TAMM, Auteur ; Kimberly D. LAKES, Auteur ; James WAXMONSKY, Auteur ; Marc LERNER, Auteur ; Joy ETCOVITCH, Auteur ; Desiree W. MURRAY, Auteur ; Maximilian MUENKE, Auteur ; Maria T. ACOSTA, Auteur ; Mauricio ARCOS-BURGOS, Auteur ; William E. PELHAM, Auteur ; Helena C. KRAEMER, Auteur ; THE M. T. A. COOPERATIVE GROUP,, Auteur . - p.663-678. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.663-678 Mots-clés : Attention-deficit/hyperactivity disorder  follow-up studies  growth  longitudinal studies  treatment trials  medication effects Index. décimale : PER Périodiques Résumé : Background The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7–10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2–16 years after baseline. Methods Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. Results For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38). Conclusions In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity. En ligne : http://dx.doi.org/10.1111/jcpp.12684 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308

---

1 (1 - 3 / 3)